Yue Wei, Ph.D.

Peer-Reviewed Articles

1. Zhang H, Li HS, Hillmer EJ, Zhao Y, Chrisikos TT, Hu H, Wu X, Thompson EJ, Clise-Dwyer K, Millerchip KA, Wei Y, Puebla-Osorio N, Kaushik S, Santos MA, Wang B, Garcia-Manero G, Wang J, Sun SC, Watowich SS. Genetic rescue of lineage-balanced blood cell production reveals a crucial role for STAT3 antiinflammatory activity in hematopoiesis. Proc Natl Acad Sci U S A. e-Pub 2018. PMID: 29463696.
2. Yang H, Fang Z, Wei Y, Bohannan ZS, Gañán-Gómez I, Pierola AA, Paradiso LJ, Iwamura H, Garcia-Manero G. Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia. Leuk Res 59:85-92, 2017. e-Pub 2017. PMID: 28599189.
3. Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Wei Y, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian HM, Hearn K, Estrov Z, Reyes S, Bueso-Ramos CE, Garcia-Manero G. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol 92(7):674-682, 2017. e-Pub 2017. PMID: 28370157.
4. Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of Achievement of Complete Cytogenetic Response on Outcome in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents. Am J Hematol 92(4):351-358, 2017. e-Pub 2017. PMID: 28076892.
5. Chamseddine AN, Cabrero M, Wei Y, Ganan-Gomez I, Colla S, Takahashi K, Yang H, Bohannan ZS, Garcia-Manero G. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk 16 Suppl:S67-73, 2016. PMID: 27521329.
6. Cabrero M, Wei Y, Yang H, Ganan-Gomez I, Bohannan Z, Colla S, Marchesini M, Bravo GM, Takahashi K, Bueso-Ramos C, Garcia-Manero G. Down-regulation of EZH2 expression in myelodysplastic syndromes. Leuk Res 44:1-7, 2016. e-Pub 2016. PMID: 26970171.
7. Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y. Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. Br J Haematol 173(1):161-5, 2016. e-Pub 2015. PMID: 26105212.
8. Zhang C, Suo J, Katayama H, Wei Y, Garcia-Manero G, Hanash S. Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines. Clin Proteomics 13:14, 2016. e-Pub 2016. PMID: 27382363.
9. Yue W, Li Y, Zhang T, Jiang M, Qian Y, Zhang M, Sheng N, Feng S, Tang K, Yu X, Shu Y, Yue C, Jing N. ESC-Derived Basal Forebrain Cholinergic Neurons Ameliorate the Cognitive Symptoms Associated with Alzheimer's Disease in Mouse Models. Stem Cell Reports 5(5):776-90, 2015. e-Pub 2015. PMID: 26489896.
10. Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia 29(7):1458-69, 2015. e-Pub 2015. PMID: 25761935.
11. Estécio MR, Maddipoti S, Bueso-Ramos C, DiNardo CD, Yang H, Wei Y, Kondo K, Fang Z, Stevenson W, Chang KS, Pierce SA, Bohannan Z, Borthakur G, Kantarjian H, Garcia-Manero G. RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. Br J Haematol 169(3):344-51, 2015. e-Pub 2015. PMID: 25612675.
12. Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, Ruisaard K, Ganan Gomez I, Bristow CA, Estecio M, Weksberg DC, Ho YW, Hu B, Genovese G, Pettazzoni P, Multani AS, Jiang S, Hua S, Ryan MC, Carugo A, Nezi L, Wei Y, Yang H, D'Anca M, Zhang L, Gaddis S, Gong T, Horner JW, Heffernan TP, Jones P, Cooper LJ, Liang H, Kantarjian H, Wang YA, Chin L, Bueso-Ramos C, Garcia-Manero G, DePinho RA. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell 27(5):644-57, 2015. PMID: 25965571.
13. Yang H, Maddipoti S, Quesada A, Bohannan Z, Cabrero Calvo M, Colla S, Wei Y, Estecio M, Wierda W, Bueso-Ramos C, Garcia-Manero G. Analysis of class I and II histone deacetylase gene expression in human leukemia. Leuk Lymphoma 56(12):3426-33, 2015. e-Pub 2015. PMID: 25944469.
14. Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 14(5):401-10, 2014. e-Pub 2014. PMID: 24875590.
15. Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, Fang Z, Nguyen M, Pierce S, Wei Y, Parmar S, Cortes J, Kantarjian H, Garcia-Manero G. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28(6):1280-8, 2014. e-Pub 2013. PMID: 24270737.
16. Gañán-Gómez I, Wei Y, Yang H, Pierce S, Bueso-Ramos C, Calin G, Boyano-Adánez Mdel C, García-Manero G. Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest. PLoS One 9(4):e93404, 2014. e-Pub 2014. PMID: 24690917.
17. Gañán-Gómez I, Wei Y, Yang H, Boyano-Adánez MC, García-Manero G. Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med 65:750-64, 2013. e-Pub 2013. PMID: 23820265.
18. Wei Y, Chen R, Dimicoli S, Bueso-Ramos C, Neuberg D, Pierce S, Wang H, Yang H, Jia Y, Zheng H, Fang Z, Nguyen M, Ganan-Gomez I, Ebert B, Levine R, Kantarjian H, Garcia-Manero G. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia 27(11):2177-86, 2013. e-Pub 2013. PMID: 23538751.
19. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia 27(10):2081-3, 2013. e-Pub 2013. PMID: 23774633.
20. Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol 88(10):831-7, 2013. e-Pub 2013. PMID: 23760779.
21. Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, Pierce S, Jia Y, Zheng H, Wang H, Wang X, Nguyen M, Wang SA, Ebert B, Bejar R, Levine R, Abdel-Wahab O, Kleppe M, Ganan-Gomez I, Kantarjian H, Garcia-Manero G. Toll-like receptor alterations in myelodysplastic syndrome. Leukemia 27(9):1832-40, 2013. e-Pub 2013. PMID: 23765228.
22. DiNardo CD, Gharibyan V, Yang H, Wei Y, Pierce S, Kantarjian HM, Garcia-Manero G, Rytting M. Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia. Am J Hematol 88(9):784-9, 2013. e-Pub 2013. PMID: 23757320.
23. Attieh Y, Geng QR, Dinardo CD, Zheng H, Jia Y, Fang ZH, Gañán-Gómez I, Yang H, Wei Y, Kantarjian H, Garcia-Manero G. Low frequency of H3.3 mutations and upregulated DAXX expression in MDS. Blood 121(19):4009-11, 2013. PMID: 23660862.
24. Kuang SQ, Fang Z, Zweidler-McKay PA, Yang H, Wei Y, Gonzalez-Cervantes EA, Boumber Y, Garcia-Manero G. Epigenetic inactivation of notch-hes pathway in human B-cell acute lymphoblastic leukemia. PLoS One 8(4):e61807, 2013. e-Pub 2013. PMID: 23637910.
25. Dimicoli S, Wei Y, Bueso-Ramos C, Yang H, Dinardo C, Jia Y, Zheng H, Fang Z, Nguyen M, Pierce S, Chen R, Wang H, Wu C, Garcia-Manero G. Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes. PLoS One 8(8):e71120, 2013. e-Pub 2013. PMID: 23976989.
26. Wei Y, Gañán-Gómez I, Salazar-Dimicoli S, McCay SL, Garcia-Manero G. Histone Methylation in myelodysplastic syndromes. Epigenomics 3(2):193-205, 2011. PMID: 22122281.
27. Yang H, Fang Z, Wei Y, Hu Y, Calin GA, Kantarjian HM, Garcia-Manero G. Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. Am J Hematol 86(2):237-8, 2011. PMID: 21264920.
28. Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, Keating M, Huang P, Garcia-Manero G. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound {beta}-phenylethyl isothiocyanate. Blood 116(15):2732-41, 2010. e-Pub 2010. PMID: 20566897.
29. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Viallet J, O'Brien S, Garcia-Manero G. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy 6(7):976-8, 2010. e-Pub 2010. PMID: 20729640.
30. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Tambaro FP, Viallet J, O'Brien S, Garcia-Manero G. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res 16(15):3923-32, 2010. e-Pub 2010. PMID: 20538760.
31. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero G. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics 5(6):499-508, 2010. e-Pub 2010. PMID: 20484983.
32. Tong WG, Wei Y, Stevenson W, Kuang SQ, Fang Z, Zhang M, Arts J, Garcia-Manero G. Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. Leuk Res 34(2):221-8, 2010. e-Pub 2009. PMID: 19682743.
33. Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, Wei Y, Jelinek J, Issa JP, Garcia-Manero G. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 22(8):1529-38, 2008. e-Pub 2008. PMID: 18528427.
34. Miele A, Braastad CD, Holmes WF, Mitra P, Medina R, Xie R, Zaidi SK, Ye X, Wei Y, Harper JW, van Wijnen AJ, Stein JL, Stein GS. HiNF-P directly links the cyclin E/CDK2/p220NPAT pathway to histone H4 gene regulation at the G1/S phase cell cycle transition. Mol Cell Biol 25(14):6140-53, 2005. PMID: 15988025.
35. Ye X, Wei Y, Nalepa G, Harper JW. The cyclin E/Cdk2 substrate p220(NPAT) is required for S-phase entry, histone gene expression, and Cajal body maintenance in human somatic cells. Mol Cell Biol 23(23):8586-600, 2003. PMID: 14612403.
36. Mitra P, Xie RL, Medina R, Hovhannisyan H, Zaidi SK, Wei Y, Harper JW, Stein JL, van Wijnen AJ, Stein GS. Identification of HiNF-P, a key activator of cell cycle-controlled histone H4 genes at the onset of S phase. Mol Cell Biol 23(22):8110-23, 2003. PMID: 14585971.
37. Xu L, Wei Y, Reboul J, Vaglio P, Shin TH, Vidal M, Elledge SJ, Harper JW. BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3. Nature 425(6955):316-21, 2003. e-Pub 2003. PMID: 13679922.
38. Wei Y, Jin J, Harper JW. The cyclin E/Cdk2 substrate and Cajal body component p220(NPAT) activates histone transcription through a novel LisH-like domain. Mol Cell Biol 23(10):3669-80, 2003. PMID: 12724424.

Other Articles

1. Wei Y, Lin C, Fu M, Zhang H, Wu M Adenovirus-transferred antisense c-myc selectively induces tumor cycle arrest. National Medical Journal of China 79:617-621, 1999.
2. Wei Y, Lin C, Fu M, Zhang H, Wu M Development of recombinant antisense cyclin D1-adnenovirus and its effect on human lung adenocarcinoma cells. Chinese Journal of Cancer Biotherapy:91-96, 1999.

Abstracts

1. Gañán-Gómez I, Ogoti Y, Marchesini M, Wei Y, Yang H, Jiang S, Bueso=Ramos CE, Garcia-Manero G, Colla S. Effect of Azacytidine on the Hematopoietic Stem and Progenitor Cell Compartments of MDS Mouse Models: Unveiling the Mechanisms of Remission and Relapse. Blood 126(23):2852, 2015.
2. Wei Y, Jia Y, Zheng H, Yang H, Bohannan ZS, Lee J, Zhao C, Bueso-Ramos CE, Chamseddine AN, Garcia-Manero G. Pharmacological Inhibition of Histone Demethylase JMJD3 Reduces Leukemia Cell Survival and Represses Production of the Cytokine CCL2 in MDS/AML. Blood 126(23):5219, 2015.
3. Chamseddine AN, Wei Y, Cabrero M, Ganan-Gomez I, Colla S, Takahashi K, Yang H, Estecio MR, Bohannan Z, Pierce S, Bueso-Ramos CE, Kantarjian HM, Jabbour E, Garcia-Manero G. PDE4 Differential Expression Is a Potential Prognostic Factor and a Therapeutic Target in Myelodysplastic Syndromes. Blood 126(23):5227, 2015.
4. Marchesini M, Ogoti Y, Ganan-Gomez I, Wei Y, Bueso-Ramos CE, Garcia-Manero G, DePinho RA, Colla S. Telomere Dysfunction-Induced DNA Damage Drives Hematopoietic Stem Cell Fate. Blood 126(23):1156, 2015.
5. Wei Y, Cabrero M, Jia Y, Zheng H, Yang H, Fang Z, Bohannan Z, Chen R, Wang H, Colla S, Wang X, Grcia-Manero G. Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes. Blood 124(21):3241, 2014.
6. CiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju H, Yang H, Wei Y, Wierda WG, Bueso-Ramos CE, Patel K, Cortes JE, Ravandi F, Kantarjian H, Garcia-Manero G. A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood 124(21):164, 2014.
7. Colla S, Ong D, Ogoti Y, Marchesini M, Mistry N, Clise-Dwyer K, Storti P, Viale A, Wei Y, Giuliani N, Yang H, D'Anca M, Estecio MR, Liang H, Kantarjian H, Wang AY, Chin L, Bueso-Ramos CE, Garcia-Manero G, DePinho R. A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome. Blood 124(21):523, 2014.
8. Marchesini M, Storti P, Ogoti Y, D'Anca M, Nezi L, Wei Y, Yang H, Ong D, Neri A, Giuliani N, Garcia-Manero G, DePinho R, Colla S. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Blood 124(21):30, 2014.
9. Estecio MR, Maddipoti S, DiNardo CD, Yang H, Stevenson W, Bueso-Ramos CE, Pierce SR, Wei Y, Garcia-Manero. Association Between RUNX3 Hypermethylation and Acute Myeloid Leukemia Inv(16) Subtype. Blood 124(21):3548, 2014.
10. Wei Y, Verma A, Cabrero M, Jia Y, Zheng H, Fang Z, Yu Y, Colla S, Bohannan Z, Bowman RV, Boultwood J, Garcia-Manero G. Association Between Downregulation of POT1 Expression and Chromosome 7 Deletion, Response to Hypomethylation Agent Treatment, and Patient Survival in Myelodysplastic Syndromes. Blood 124(21):4663, 2014.
11. Wei Y, Jia Y, Zheng H, Yang H, Chen R, Wang H, Wang X, Garcia-Manero G. Assessment Of EZH2 Expression In CD34+ Bone Marrow Progenitor Cells Of Patients Of Myelodysplastic Syndromes (MDS). Blood 122(21):2805, 2013.
12. Wei Y, Jia Y, Zheng H, Yang H, Fang Z, Colla S, Garcia-Manero G. Down-Regulated Expression Of Protection Of Telomeres 1 (POT1) Gene In Bone Marrow Hematopoietic Progenitor Cell Compartment Has Prognostic Value In Myelodysplastic Syndromes (MDS). Blood 122(21):1511, 2013.
13. Yang H, Bueso-Ramos CE, DiNardo CD, Estecio MR, Davanlou M, Geng Q, Fang Z, Nguyen M, Pierce S, Wei Y, Parmar S, Cortes JE, Kantarjian HM, Garcia-Manero G. Expression Of Immune Checkpoints PD-L1, PD-L2, PD-1 and CTLA4 Predict For Prognosis and Resistance To Hypomethylating Agents (HMAs) In Myelodysplastic Syndromes (MDS). Blood 122(21):2767, 2013.
14. Ganan-Gomez I, Wei Y, Yang H, Boyano-Adanez MC, Garcia-Manero G. Overexpression Of Mir-125a In Bone Marrow CD34+ cells Of Patients With Myelodysplastic Syndrome Is Correlated To a Poor Prognosis and May Contribute To The Pathogenesis Of The Disease Through The Modulation Of NF-Kb Activation and Enhancement Of Differentiation Arrest. Blood 122(21):5206, 2013.
15. Fang J, Siu X, Barker B, Bolanos L, Wei Y, Garcia-Maanero G, Starczynowski DT. Disease-Relevant Expression Of TRAF6 In Mouse HSC Results In An MDS-Like Disease. Blood 122(21):101, 2013.
16. Wei Y, Bueso-Ramos CE, Yang H, Jia Y, Zheng H, Colla S, Nguyen M, Fernandez M, Kantarjian HM, Garcia-Manero G. Serum Amyloid Protein A 1 (hSAA1) Is Overexpressed in Myelodysplastic Syndromes and Potentially Mediates Toll-Like Receptor 2 Innate Immunity Signaling in CD34+ Hematopoietic Stem Cells. Blood 120(1703), 2012.
17. Yang H, Bueso-Ramos CE, Pierce SA, Wei Y, Fang Z, Nguyen M, Fernandez M, Cardenas-Turanzas M, Kantarjian HM, Garcia-Manero G. Expression Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Myelodysplastic Syndromes (MDS): Level of MMP-9 Is Associated with Improved Prognosis in MDS Patients. Blood 120(3845), 2012.
18. Attieh Y, Wei Y, Yang H, Jia Y, Zheng H, Fang Z, Kantarjian HM, Garcia-Manero. Low Frequency of Molecular Alterations of H3.3-Atrx-Daxx Chromatin Remodeling Component Genes in Myelodysplastic Syndromes (MDS). Blood 120(3844), 2012.
19. Yang H, Bueso-Ramos CE, Pierce SA, Wei Y, Zhihong F, Nguyen M, Fernandez M, Cardenas-Turanzas M, Kantarjian HM, Garcia-Manero G. Upregulation of Focal Adhesion Kinase, a Potential Therapeutic Target, in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Blood 120(2827), 2012.
20. Wei Y, Chen R, Dimicoli S, Bueso-Ramos CE, Neuberg DS, Pierce SA, Yang H, Jia Y, Zheng H, Fang Z, Nguyen M, Fernandez M, Wang SA, Kantarjian HM, Garcia-Manero G. Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS). Blood 120(3810), 2012.
21. Yang H, Bueso-Ramos CE, Parmar S, Wei Y, Fang Z, Nguyen M, Fernandez M, Pierce SA, Geng Q, Kantarjian HM, Cortes JE, Garcia-Manero G. Induction of PD-1 and PD-1 Ligand Expression by Hypomethylating Agents (HMA) in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Suggest a Role for T Cell Function in Clinical Resistance to HMAs. Blood 120(3810), 2012.
22. Dimicoli S, Wei Y, Chen R, Bueso-Ramos CE, Pierce SA, Yang H, Jia Y, Zheng H, Fang Z, Ganan-Gomez I, Nguyen M, Fernandez M, Kantarjian HM, Garcia-Manero G. Toll-Like Receptor (TLR) Signaling Adaptor Protein MYD88 in Myelodysplastic Syndromes (MDS). Blood 120(556), 2012.
23. Tambaro FP, Wierda WG, Pierce S, Yang H, Wei Y, Fang Z, Kantarjian HM, Garcia-Manero G. ROS Activation Independent From Iron Overload in MDS. Blood 118(2798), 2011.
24. Wei Y, Calin G, Jia Y, Zheng H, McCay S, Yang H, Fang Z, Garcia-Manero G. Analysis of Regulatory miRNAs of Histone Demethylase JMJD3 In MDS CD34+ Hematoprogenitor Cells. Blood 116(11), 2010.
25. Yang H, Fang Z, Wei Y, Hu Y, Calin G, Kantarjian HM, Garcia-Manero G. Levels of Mir-29b or Mir-101 Do Not Predict Response In Patients (pts) with Acute Myelogenous Leukemia (AML) Treated with the Combination of 5-Azacytidine, Valproic Acid and ATRA. Blood 116(11), 2010.
26. Tambaro FP, Vigil C, Hu Y, Yang H, Fang Z, Jia JY, Wei Y, Kantarjian HM, Altucci L, Ferrara F, Garcia-Manero G. Levels of Nrf2 and Keap1 Are Associated with Poor Prognostic Features In Myelodysplastic Syndromes (MDS). Blood 116(11), 2010.
27. Wei Y, Chen R, Bueso-Ramos C, Yang H, Jia Y, Fang Z, Garcia-Manero G. Use of genome-wide CHIP-SeqSeq analysis allows identification of deregulated molecular pathways in myelodysplastic syndromes (MDS). CPRIT Innovations in Cancer Prevention and Research Conference:31, 2010.
28. Wei Y, Chen R, Bueso-Ramos CE, Wang H, Song X, Wang J, Yao H, Nguyen M, Fernandez M, Yang H, Garcia-Manero G. Genome-Wide Chip-Seq Analysis of Histone Methylation Reveals Modulators of NF-{kappa}B signalling and the Histone Demethylase JMJD3 as Implicated in Disease Progression in Myelodysplastic Syndrome (MDS). Blood 114(11), 2009.
29. Tong W, Wei Y, Stevenson W, Kuang SQ, Arts J, Garcia-Manero G. Antileukemia Activity of JNJ-26481585, a Potent Second-Generation Histone Deacetylase Inhibitor. Blood 112(11), 2008.
30. Maddipoti SC, Bueso-Ramos C, Yang H, Fernandez M, Kuang S, Stevenson W, Wei Y, Pierce S, Garcia-Manero G. Epigenetic Silencing of the RUNX3 Gene by Promoter Hypermethylation in Patients with Myeloid Leukemia. Blood 112(11), 2008.
31. Wei Y, Kadia T, Tong W, O'Brien S, Viallet J, Garcia-Manero G. The Combination of a Histone Deacetylase (HDAC) Inhibitor with the BCL-2 Inhibitor GX15-070 Has Synergistic Antileukemia Effect by Inducing Both Apoptotic and Autophagic Pathways. Blood 112(11), 2008.